Early detection of RA‑ILD—A novel screening protocol with pulmonary function testing and lung ultrasound
Zeitschrift für Rheumatologie · 2026
DOI: 10.1007/s00393-025-01775-0 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Zeitschrift für Rheumatologie, 2026. Verfasst von Carina Fischinger und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pneumology, LMU University Hospital Munich, Munich, Germany. Carina.Fischinger@gmx.de. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Arthritis, Rheumatoid, Respiratory Function Tests, Mass Screening. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Klinikum der Universität München.
Abstract (Originalsprache)
Background
Seropositive rheumatoid arthritis (RA) is linked to cardiovascular and pulmonary morbidity. Nevertheless, there is currently no standardized screening method for early detection of RA-associated interstitial lung disease (ILD).
Purpose
This study proposes using pulmonary function testing (PFT) combined with lung ultrasound (LUS) as additional and radiation-free method to screen for ILD inRF- and ACPA-positive RA patients. Particularly in light of the increased therapeutic options, early detection of RA-ILD is associated with better outcome.
Methods
We included 214 consecutive patients with diagnosed RF- and ACPA-positive RA in our prospective study. These patients underwent PFT including spirometry, body plethysmography, and cardiopulmonary exercise testing as well as ultrasound examination of the lungs and the heart.
Results
A total of 203 patients (mean age 59 ± 12 years, 24% male, 43% current or previous smokers) were examined. The overall average RA duration was 8 ± 7 years, with 32% of all patients suffering from an erosive disease course. In PFT, 60 patients (30%) showed a limitation in forced vital capacity (FVC) as well as a diffusion disorder, defined as FVC and diffusing capacity of the lung for carbon monoxide (DLCOc) ≤ 80%. Ultrasound changes were seen in 107 patients (53%), with 29% ( n = 58) showing typical LUS patterns suspicious of ILD. In summary, ILD was suspected in almost 16% of patients ( n = 32). With the combination of PFT and LUS, our ILD screening protocol achieves a high level of sensitivity (93%) and specificity of 72%.
Conclusion
Our study contributes to the growing body of evidence supporting the use of LUS for screening for RA-associated ILD. We propose that LUS, in conjunction with PFT, serves as a suitable imaging tool for ILD screening in RA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pneumology, LMU University Hospital Munich, Munich, Germany. Carina.Fischinger@gmx.de.
- Rheumacare, SYNLAB MVZ für Rheumatologie, Planegg, Germany.
- Department of Pneumology, Augustinum Hospital Munich, Munich, Germany.
- Clinic of Pulmonary Medicine, Seefeld-Hechendorf, Germany.
- Department of Pneumology, LMU University Hospital Munich, Munich, Germany.
- Department of Pneumology, Medical University Graz, Graz, Austria.
Förderung
- Klinikum der Universität München
Zitieren
APA
Fischinger, C., Popp, F., Reichenberger, F., Kneidinger, N., Tiede, R., von Wulffen, W., & Welcker, M. (2026). Early detection of RA‑ILD—A novel screening protocol with pulmonary function testing and lung ultrasound. Zeitschrift für Rheumatologie. https://doi.org/10.1007/s00393-025-01775-0
Vancouver
Fischinger C, Popp F, Reichenberger F, Kneidinger N, Tiede R, von Wulffen W, et al. Early detection of RA‑ILD—A novel screening protocol with pulmonary function testing and lung ultrasound. Zeitschrift für Rheumatologie. 2026. doi:10.1007/s00393-025-01775-0
BibTeX
@article{Fischinger2026,
author = {Fischinger, Carina and Popp, Florian and Reichenberger, Frank and Kneidinger, Nikolaus and Tiede, Robin and von Wulffen, Werner and Welcker, Martin},
title = {Early detection of RA‑ILD—A novel screening protocol with pulmonary function testing and lung ultrasound},
journal = {Zeitschrift für Rheumatologie},
year = {2026},
doi = {10.1007/s00393-025-01775-0}
}
EUVIMED